Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MG1 MA3 - Turnstone Biologics

Next Previous
Drug Profile

MG1 MA3 - Turnstone Biologics

Alternative Names: Ad MAGEA3; Marabex; MG1 Maraba/MAGE-A3; MG1-MAGEA3; MG1MA3

Latest Information Update: 08 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Children's Hospital of Eastern Ontario; McMaster University; University of Ottawa
  • Developer Canadian Cancer Society Research Institute; Turnstone Biologics
  • Class Cancer vaccines; Oncolytic viruses
  • Mechanism of Action Immunostimulants; Neoplasm antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 08 Oct 2021 Phase-I/II development is still ongoing Canada (NCT02285816)
  • 06 Apr 2021 Turnstone Biologics withdraws the phase I Pelican trial in Squamous cell carcinoma prior to enrolment due to inadequate study drug supply (NCT03773744)
  • 24 May 2020 Turnstone Biologics completes the phase I/II Sandpiper trial in Non-small cell lung cancer (Combination therapy, Second-line therapy or greater, Late-stage disease) in Canada (IV) (IM) (NCT02879760)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top